MGC Pharmaceuticals Ltd appoints new joint company secretary in Nadine Barry proactiveinvestors.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from proactiveinvestors.co.uk Daily Mail and Mail on Sunday newspapers.
MGC Pharmaceuticals Ltd (ASX: MXC or the Company ) advises the Company s Board and independent committees have, following the recent dual listing on the London Stock Exchange, and in conjunction with the Company s key advisors in the United Kingdom, agreed market appropriate changes to the remuneration and equity incentive structures of the Executive Directors and Key Management Personnel. This includes a new performance rights program structured to retain the services of key personnel managing the Company s business and to bring in line with similar listed companies in the bio-pharma sector in the United Kingdom. In addition, the Company announces the change of Company Secretary, Mrs Narelle Warren resigning as Joint Company Secretary of the Company with an effective date of 07 April 2021. The Board would like to express its appreciation to Mrs Warren for her contribution to the Company during her tenure which included the successful du
Notice of Meeting and Incentive Share Plan MGC Pharmaceuticals Ltd (ASX: MXC, MGC or the Company ), is pleased to provide a copy of its Notice of General Meeting, to be held at 4pm WST 31 March 2021. Furthermore, in recognition of their contribution to the Company s success, it intends to issue performance rights under its proposed Employee Securities Incentive Plan ( Plan ) to its officers and employees in mid-May 2021. The Company will make the offer if shareholders approve the Company s Incentive Plan (Resolution 5) at the upcoming general meeting. Shareholder approval will not be sought for the issue of the performance rights themselves. The Company has resolved to offer 14,800,000 performance rights in total which will vest upon the eligible employees having either 18 months of continuous service to the Company up to 30 June 2021, or if employment commenced on or after 1 January 2020, contin